The burden of drug resistance tuberculosis in Ghana; results of the First National Survey.
Augustina Angelina AnnanAlexander KwartengSampson Twumasi-AnkrahMichael OwusuRejoice Agyeiwaa ArthurRexford Mawunyo DumeviLouis Adu-AmoahNicholas AddofohPortia Boakye OkyereFrancisca DzataFrank BonsuYaw Adusi-PokuKatharina KranzerAndrew SirokaWayne van GemertAnna DeanEllis Owusu-DaboPublished in: PloS one (2021)
Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.
Keyphrases
- mycobacterium tuberculosis
- newly diagnosed
- pulmonary tuberculosis
- risk factors
- end stage renal disease
- ejection fraction
- emergency department
- public health
- randomized controlled trial
- type diabetes
- cross sectional
- cystic fibrosis
- multidrug resistant
- quality improvement
- endothelial cells
- case report
- social media
- human health
- weight loss
- antiretroviral therapy
- combination therapy
- adverse drug
- replacement therapy
- hiv infected